Decreased plasma levels of nitric oxide (NO) derivatives in obstructive sleep apnea (OSA): response to automatic positive airway pressure (APAP) therapy

P. Pinto, C. Barbara, M. Guarino, R. Patarrao, M. Mota Carmo, P. Macedo, J. Teixeira, R. Dias, C. Canhao, M. J. Marques Gomes (Lisbon, Portugal)

Source: Annual Congress 2007 - Cardiovascular and respiratory control in obstructive sleep apnoea
Session: Cardiovascular and respiratory control in obstructive sleep apnoea
Session type: Thematic Poster Session
Number: 2024
Disease area: Sleep and breathing disorders

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Pinto, C. Barbara, M. Guarino, R. Patarrao, M. Mota Carmo, P. Macedo, J. Teixeira, R. Dias, C. Canhao, M. J. Marques Gomes (Lisbon, Portugal). Decreased plasma levels of nitric oxide (NO) derivatives in obstructive sleep apnea (OSA): response to automatic positive airway pressure (APAP) therapy. Eur Respir J 2007; 30: Suppl. 51, 2024

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Exhaled nitric oxide in obstructive sleep apnea (OSA) patients: short and long term response to automatic positive airway pressure (APAP) therapy
Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea
Year: 2007


The influence of short-term therapy of continous positive airway pressure (CPAP) on exhaled nitric oxide concentration (FENO) in patients with obstructive sleep apnea (OSA)
Source: Eur Respir J 2005; 26: Suppl. 49, 357s
Year: 2005

Alveolar but not airway fractional exhaled nitric oxide concentration (FENO) is decreased in obstructive sleep apnea syndrome (OSAS)
Source: Eur Respir J 2003; 22: Suppl. 45, 467s
Year: 2003

Plasma endothelin-1 (ET-1) levels in obstructive sleep apnea (OSA) patients and effect of continouous positive airway pressure (CPAP) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 40s
Year: 2005

impact of continous positive airway pressure therapy on exhaled nitic oxide in obstructive sleep apnea syndrome
Source: International Congress 2019 – Clinical problems from non-malignant pleural disease to hypoventilation
Year: 2019

Concentration of exhaled nitric oxide (FENO) in patients with obstructive sleep apnea
Source: Eur Respir J 2004; 24: Suppl. 48, 118s
Year: 2004

Oral nitric oxide in obstructive sleep apnoea (OSA)
Source: Annual Congress 2008 - Metabolic syndrome and systemic inflammation in obstructive sleep apnoea
Year: 2008


Effect of nasal CPAP on exhaled nitric oxide in patients with obstructive sleep apnea
Source: Eur Respir J 2007; 30: Suppl. 51, 332s
Year: 2007

Increased alveolar nitric oxide by trumpet model in patients with obstructive sleep apnoea
Source: Annual Congress 2012 - CPAP: beneficial effects on different aspects of health
Year: 2012


Influence of nasal obstruction (NO) on obstructive sleep apnea (OSA) severity and continuous positive airway pressure (CPAP) adaptation problems
Source: Annual Congress 2010 - The upper airway and oral appliances
Year: 2010

Oxydative stress in obstructive sleep apnea: Value of fractional exhaled nitric oxide measurement
Source: International Congress 2018 – Sleep-disordered breathing: biomarkers and genetics and the role of hypoxia, insomnia, movement disorders and sleep quality
Year: 2018

Catecholamines and obstructive sleep apnea (OSA) severity: response to positive airway pressure (PAP) therapy
Source: Annual Congress 2009 - Continuous positive airway pressure therapy in obstructive sleep apnoea
Year: 2009


Effect of automatic positive airway pressure (APAP) therapy on blood pressure (BP) in patients with obstructive sleep apnea (OSA) and hypertension
Source: Annual Congress 2008 - Clinical aspects of continuous positive airway pressure therapy
Year: 2008


Differential assessment of airway inflammation in chronic obstructive pulmonary disease (COPD) by measurements of exhaled nitric oxide (NO) derived from peripheral vs. central airways
Source: Eur Respir J 2003; 22: Suppl. 45, 279s
Year: 2003

Can fractional exhaled nitric oxide be useful to differentiate asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) from COPD-only
Source: Virtual Congress 2020 – Air pollution and comorbidities
Year: 2020

Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms
Source: Eur Respir J 2002; 20: 841-845
Year: 2002



Cough sensitivity, airway responsiveness and exhaled nitric oxide (eNO) for predicting the response to bronchodilator therapy (BDT) in patients with chronic non-productive cough
Source: Annual Congress 2010 - Cough, airway hyperresponsiveness and asthma control
Year: 2010

Positional obstructive sleep apnea (OSA) and automatic positive airway pressure (APAP) therapy
Source: Annual Congress 2012 - Technology, screening and questionnaires in OSA
Year: 2012


Is Fractional exhaled nitric oxide (FeNO) test reliable in the differentiation of chronic obstructive pulmonary disease (COPD) and ACOS (asthma-COPD overlap syndrome)?
Source: International Congress 2017 – Lung function testing in different patient categories
Year: 2017


Nitric oxide and obstructive sleep apnea syndrome (OSAS): reflection of inflammation and oxidative stress
Source: Annual Congress 2008 - Metabolic syndrome and systemic inflammation in obstructive sleep apnoea
Year: 2008